Thông tin thuốc gốc
Chỉ định và Liều dùng
Skin and skin structure infections
Adult: 300 mg every 12 hours, via infusion over 60 minutes for 5-14 days.

Skin and skin structure infections
Adult: 450 mg every 12 hours for 5-14 days.
Suy thận
Estimated GFR (eGFR) <15 mL/min/1.73m2, ESRD, patients on haemodialysis: Not recommended.

eGFR <15 mL/min/1.73m2, ESRD, patients on haemodialysis: Not recommended. eGFR 15-29 mL/min/1.73m2: 200 mg every 12 hours.
Cách dùng
May be taken with or without food. Take at least 2 hr before or 6 hr after antacids containing Mg or Al, sucralfate, & supplements containing Zn or Fe.
Hướng dẫn pha thuốc
IV Infusion: Reconstitute vials labelled as containing 300 mg with 10.5 mL NaCl 0.9% or dextrose 5% in water to provide a solution containing 25 mg/mL. Shake the vial vigorously to completely dissolve. Further dilute with NaCl 0.9% or dextrose 5% inj to a total volume of 250 mL with a final concentration of 1.2 mg/mL.
Tương kỵ
Incompatible with solutions containing multivalent cations (e.g. Ca, Mg).
Chống chỉ định
Hypersensitivity to delafloxacin or other fluoroquinolones. Patient with known history of tendon disorders (e.g. tendinitis or tendon rupture), peripheral neuropathy, myasthenia gravis. Concomitant administration with live vaccines.
Thận trọng
Patient with known or suspected CNS disorder (e.g. severe cerebral arteriosclerosis, epilepsy), risk factors that may predispose to seizures, risk factors for tendon rupture (e.g. solid organ transplant recipients, history of rheumatoid arthritis). Renal impairment. Elderly.
Tác dụng không mong muốn
Significant: Hyperglycaemia, hypoglycaemia leading to coma, superinfection (e.g. Clostridium difficile-associated diarrhoea (CDAD) or pseudomembranous colitis), irreversible tendinitis or tendon rupture, peripheral neuropathy, CNS effects (e.g. seizures, increased, intracranial pressure); toxic psychosis (e.g. disturbances in attention, disorientation, agitation, nervousness, memory impairment, depression, suicidality, delirium).
Gastrointestinal disorders: Nausea, vomiting, diarrhoea.
Investigations: Elevated transaminases.
Nervous system disorders: Headache.
Potentially Fatal: Hypersensitivity reactions (e.g. anaphylaxis).
Thông tin tư vấn bệnh nhân
This drug may cause dizziness and lightheadedness, if affected, do not drive or operate machinery.
Chỉ số theo dõi
Monitor serum creatinine, GFR levels, CBC, LFT, blood glucose levels. Monitor for signs and symptoms of hypersensitivity reactions, tendon problems, and infection. Perform culture and sensitivity tests prior to initiating therapy, test for C. difficile if diarrhoea develops.
Tương tác
May enhance hypoglycaemic effect of oral hypoglycaemic agents. Decreased absorption by forming chelates with antacids containing Al, Mg.
Potentially Fatal: May diminish therapeutic effect of live vaccines.
Tác dụng
Mechanism of Action: Delafloxacin is a fluoroquinolone anti-infective agent, which inhibits bacterial topoisomerase IV and DNA gyrase (topoisomerase II) enzymes which are essential for bacterial DNA replication, transcription, repair and recombination thereby impeding bacterial growth.
Absorption: Bioavailability: 58.8%. Time to peak plasma concentration: Approx 1 hour.
Distribution: Plasma protein binding: Approx 84%, mainly to albumin.
Metabolism: Primarily metabolised via glucuronidation by uridine diphosphate-glucuronosyltransferase (UGT) 1A1, 1A3, and 2B15.
Excretion: Via urine (50% (oral), 65% (IV), as unchanged drug); faeces (48% (oral), 28% (IV), as unchanged drug. Elimination half-life: 4.2-8.5 hours (oral); 3.7 hours (IV).
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Delafloxacin, CID=487101, (accessed on Jan. 20, 2020)

Bảo quản
Store between 20-25°C. Reconstituted solution: Store between 20-25°C or refrigerate between 2-8°C for up to 24 hours. Do not freeze.
Phân loại MIMS
Phân loại ATC
J01MA23 - delafloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.
Tài liệu tham khảo
Anon. Delafloxacin. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. Accessed 03/09/2018 .

Anon. Delafloxacin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 03/09/2018 .

Baxdela (Melinta Therapeutics, Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 03/09/2018 .

Baxdela (Melinta Therapeutics, Inc.). U.S. FDA. Accessed 03/09/2018 .

Buckingham R (ed). Delafloxacin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. . Accessed 03/09/2018 .

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Delafloxacin từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in